Connect with us


Stock Market This Week: What To Watch 9/19-9/23

Whether trading penny stocks or higher priced stocks, here’s what to consider in the stock market this week September 19,2022 to September 23, 2022.



Stock Market Outlook For This Week: September 19th to September 23rd

Last week in the stock market was another volatile one full of massive price swings thanks to surprising economic data. The jewels of the week were US Producer Price (PPI) and Consumer Price (CPI) data with little on the Fed speak front. We also saw jobs data and retail sales briefly help bulls but to no avail. All of this set the stage for what could be one of the busiest and most volatile weeks of September.

That’s because this is Fed Meeting (FOMC meeting) week. This week reveals the long-awaited rate hike decision that will likely make its mark on investors. More than that, however, we’ve added some critical global economic events that could play a part in the stock market this week.

Whether you’re trading penny stocks or higher-priced names, monetary policy decisions could sway daily trends. The Bank of England, Bank of Japan, Germany, Great Britain, and the Eurozone all have economy & monetary policy data coming throughout the week. In addition to US Fed speak, it may also be essential to watch what European Central Bank (ECB) members have to say about their outlook on the economy.

Stock Dropped Ahead Of September FOMC Meeting This Week

Thanks to the surprise inflation data, markets tumbled last week. The major index ETFs including the S&P 500 (NYSEARCA: SPY), Nasdaq (NASDAQ: QQQ), Russell 2000 Small Cap Index (NYSEARCA: IWM) and Dow (NYSEARCA: DIA), fell lower as investors pivoted to begin pricing in a more aggressive Federal Reserve. Not only was this based on economic data but also reports from companies like FedEx (NYSE: FDX), which missed revenue estimates while also withdrawing full-year guidance.

When asked if the economy is going into a worldwide recession, FedEx CEO Raj Subramaniam said in an interview with CNBC’s Jim Cramer, “I think so. But you know, these numbers, they don’t portend very well…I’m very disappointed in the results that we just announced here, and you know, the headline really is the macro situation that we’re facing.”

[Read More] Making Money With Penny Stocks When the Market Crashes

The market is also pricing in a high chance of a 75 basis point hike and even as high as a 100 basis point hike at the September FOMC meeting. Is this the week the stock market crash puts in new lows for 2022?

Let’s see what’s ahead in the stock market this week:

What To Watch In The Stock Market This Week

With the addition of global economic data, it will be essential to understand that this may or may not be catalysts depending on other events in the US markets.

Stock Market News & Events For Monday, 9/19

The stock market on Monday, September 19, 2022, is a lighter day for economic events, but that doesn’t mean there aren’t things to know about. The National Association of Home Builders (NAHB) Housing Market Index data is coming out just after the opening bell. A higher-than-expected read is generally bullish for the US dollar and vice versa when it’s lower than expected. The NAHB forecast is 47 right now, which would be lower than the previous read for August, which came in at 49. Since hitting 79 in April, the NAHB Index has continued declining month-over-month.

After the stock market closes, Japan’s national CPI and Core CPI for August will get reported. Expectations for Core CPI are set at 2.7%, which would be slightly higher than the previous CPI read of 2.4%. Last week we saw how surprise CPI and PPI data could move markets. Whether or not Japan’s economic data experiences the same is to be seen but surely will be revealed Monday evening.

Stock Market News & Events For Tuesday, 9/20

The stock market on Tuesday, September 20, 2022, begins to see some added speculation based on economic data and ECB speak. An hour before the US market opens, we’ll get the August Building Permits, and Housing Starts data. These are expected to reach 1.610 million and 1.445 million, respectively. Both would be slightly lower than the previous reads, which came in at 1,685 million and 1.446 million. Like NAHB data, starts and permits have declined throughout the year on a month-over-month basis.

ECB member McCaul speaks at 11 AM ET, while ECB President Lagarde speaks at 1 PM ET. The latter of these two speaking engagements could bring a bit more volatility depending on what is said. Since the ECB sets short-term interest rates, Christine Lagarde’s outlook could weigh heavily upon the future of monetary policy and rate shifts for the Eurozone.

Tuesday is also when the September FOMC meeting begins.

Stock Market News & Events For Wednesday, 9/21

That last sentence was a lead-in to what could be one of the most important days of the stock market this week. We get more housing data from Mortgage Rates, Applications, and Purchase Index. Existing Home Sales for August will also be in the spotlight early on. For those watching energy stocks, Crude Oil Inventories come out around the same time as Home Sales.

[Read More] 3 Hot Penny Stocks To Buy According To Insiders In September

But the 2 PM ET to 3 PM ET hour will be important and could move markets. That’s because the September Fed Meeting comes to completion, and we’ll get confirmation on the future of monetary policy, including the latest rate hike figures. The FOMC press conference at 2:30 PM ET on September 21st will likely add more detail to digest as it always does.

Stock Market News & Events For Thursday, 9/22

The stock market on Thursday, September 22, 2022, will likely be the FOMC hangover day for markets, but no time to take a breather. That’s because the Bank of England interest rate decision and BoE Monetary Policy Committee (MPC) minutes come out early in the US premarket session at 7 AM ET. This is a lead-in to the latest jobs data at 8:30 AM ET, including initial, continuing, and 4-week average jobless claims.

Stock Market News & Events For Friday, 9/23

The stock market on Friday, September 23, 2022, caps off the hectic week. We’ll get early morning economic data from Germany, the Eurozone, and the UK. Plus, US Manufacturing Services PMI comes out right after the stock market opens. But again, FOMC and Fed events will likely captain the ship. Fed Chair Jerome Powell is set to speak at 2 PM ET.

What’s going on with the Fed on September 23rd? The Federal Reserve Board hosts a Fed Listens event: Transitioning to the Post-pandemic Economy. Representatives from many sectors will share perspectives on the pandemic’s impact on reshaping the economy and workforce.

They will also discuss challenges and opportunities that exist during the transitional period. Fed Chair Jerome Powell provides opening remarks while Vice Chair Brainard and Governor Bowman moderate conversations from organizational leaders.

[Read More] Hot Penny Stocks To Buy For Under $1 Right Now

Stock Market Snap Shot For This Week

This is just a brief snapshot of what to watch in the stock market this week. These are some of the higher-profile catalysts that could sway sentiment and dictate the overall trends. This Week’s FOMC Meeting could mean that this is one of the Biggest Weeks of 2022.

Every trader and investor in the stock market today is asking the same questions:

  • What Happens Next in The Stock Market with this week’s Fed Meeting?
  • Is the stock market crash going to take stocks to new 2022 lows?
  • What other stock market news can move the market this week?
  • How Can I Make Money Trading in The Stock Market?
  • What stocks to buy now in 2022?

The answer to all of these questions will come down to the outcome of this week’s Federal Reserve Meeting & press conference. When is the September 2022 FOMC Meeting? It begins on Tuesday, September 20, 2022, and concludes on September 21, 2022, with the Fed Press Conference at 2:30 PM ET.

What’s Next For The Stock Market?

Will Fed Chair Jerome Powell raise rates 75 basis points or is a 100 bps hike in store? Will the recession be avoided and is a soft landing really possible after last week’s surprise August CPI data and August PPI inflation data?

Many investors are already working overtime in the stock market this week, giving countless stock market and trading predictions as well as their stock market outlook and trading game plan for this week. They will surely weigh in on the stock market crash, recession, inflation, stagflation, and this stock market game, in general.

If you ever wondered How to start investing in the stock market, How the stock market works, or asked yourself, “Is this a stock market for beginners,” it’s time to pay attention.

True Trading Group is hosting a stock market live stream that will answer those very questions and a lot more! Get Ready To Learn To Trade & Profit LIVE with True Trading Group, Tonight, Sunday, 9/18/2022. They host free stock market live trading predictions for the week ahead on YouTube at 8:30 PM ET.

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Stock Market This Week: What To Watch 9/19-9/23 appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide…



Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide Black Lives Matter riots in the summer of 2020, some elite colleges and universities shredded testing requirements for admission. Several years later, the test-optional admission has yet to produce the promising results for racial and class-based equity that many woke academic institutions wished.

The failure of test-optional admission policies has forced Dartmouth College to reinstate standardized test scores for admission starting next year. This should never have been eliminated, as merit will always prevail. 

"Nearly four years later, having studied the role of testing in our admissions process as well as its value as a predictor of student success at Dartmouth, we are removing the extended pause and reactivating the standardized testing requirement for undergraduate admission, effective with the Class of 2029," Dartmouth wrote in a press release Monday morning. 

"For Dartmouth, the evidence supporting our reactivation of a required testing policy is clear. Our bottom line is simple: we believe a standardized testing requirement will improve—not detract from—our ability to bring the most promising and diverse students to our campus," the elite college said. 

Who would've thought eliminating standardized tests for admission because a fringe minority said they were instruments of racism and a biased system was ever a good idea? 

Also, it doesn't take a rocket scientist to figure this out. More from Dartmouth, who commissioned the research: 

They also found that test scores represent an especially valuable tool to identify high-achieving applicants from low and middle-income backgrounds; who are first-generation college-bound; as well as students from urban and rural backgrounds.

All the colleges and universities that quickly adopted test-optional admissions in 2020 experienced a surge in applications. Perhaps the push for test-optional was under the guise of woke equality but was nothing more than protecting the bottom line for these institutions. 

A glimpse of sanity returns to woke schools: Admit qualified kids. Next up is corporate America and all tiers of the US government. 

Tyler Durden Mon, 02/05/2024 - 17:20

Read More

Continue Reading


Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…



To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading


Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….



Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 


About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

Read More

Continue Reading